

DAFTAR PUSTAKA

- Alizadeh, A., Eisen, M., Davis, R., Ma, C., Lossos, I., Rosenwald, A., et al. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. *Nature*, 403(6769), pp.503-511.
- Bernd, H., Ziepert, M., Thorns, C., Klapper, W., Wacker, H., Hummel, M., et al. 2009. Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials. *Haematologica*, 94(11), pp.1569-1580.
- Camara, D., Stefanoff, C., Pires, A., Soares, F., Biasoli, I., Zalcborg, I., et al. 2007. Immunoblastic morphology in diffuse large B-cell lymphoma is associated with a nongerminal center immunophenotypic profile. *Leukemia & Lymphoma*, 48(5), pp.892-896
- Campo, E., Swerdlow, S., Harris, N., Pileri, S., Stein, H. and Jaffe, E. 2011. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood*, 117(19), pp.5019-5032.
- Carbone, A., Gloghini, A., Kwong, Y. and Younes, A. 2014. Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy. *Annals of Hematology*, 93(8), pp.1263-1277.
- Choi, W., Weisenburger, D., Greiner, T., Piris, M., Banham, A., Delabie, J., et al. 2009. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. *Clinical Cancer Research*, 15(17), pp.5494-5502.
- Colomo, L. 2002. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. *Blood*, 101(1), pp.78-84.

- De Paepe, P. 2005. Large Cleaved and Immunoblastic Lymphoma May Represent Two Distinct Clinicopathologic Entities Within the Group of Diffuse Large B-Cell Lymphomas. *Journal of Clinical Oncology*, 23(28), pp.7060-7068.
- Diebold, J., Anderson, J., Armitage, J., Connors, J., MacLennan, K., Müller-Hermelink, H., et al. 2002. Diffuse Large B-cell Lymphoma: A Clinicopathologic Analysis of 444 Cases Classified According to the Updated Kiel Classification. *Leukemia & Lymphoma*, 43(1), pp.97-104.
- Flowers, C., Shenoy, P., Borate, U., Bumpers, K., Douglas-Holland, T., King, N., et al. 2013. Examining racial differences in diffuse large B-cell lymphoma presentation and survival. *Leukemia & Lymphoma*, 54(2), pp.268-276.
- Frick, M., Dorken, B. and Lenz, G. 2011. The molecular biology of diffuse large B-cell lymphoma. *Therapeutic Advances in Hematology*, 2(6), pp.369-379.
- Friedberg, J. and Fisher, R. 2008. Diffuse Large B-Cell Lymphoma. *Hematology/Oncology Clinics of North America*, 22(5), pp.941-952.
- Gouveia, G., Siqueira, S. and Pereira, J. 2012. Pathophysiology and molecular aspects of diffuse large B-cell lymphoma. 34(6), pp.447-451.
- Gurbaxani, S., Anastasi, J. and Hyjek, E. 2009. Diffuse Large B-Cell Lymphoma—More Than a Diffuse Collection of Large B Cells An Entity in Search of a Meaningful Classification. 133, pp.1121-1134.
- Habermann, T. 2006. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma. *Journal of Clinical Oncology*, 24(19), pp.3121-3127.

- Hans, C. 2004. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. *Blood*, 103(1),pp.275-282.
- Martelli, M., Ferreri, A., Agostinelli, C., Di Rocco, A., Pfreundschuh, M. and Pileri, S. 2013. Diffuse large B-cell lymphoma. *Critical Reviews in Oncology/Hematology*, 87(2), pp.146-171.
- Menon, M., Pittaluga, S. and Jaffe, E. 2012. The Histological and Biological Spectrum of Diffuse Large B-Cell Lymphoma in the World Health Organization Classification. *The Cancer Journal*, 18(5), pp.411-420.
- Ott, G., Ziepert, M., Klapper, W., Horn, H., Szczepanowski, M., Bernd, H., et al. 2010. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. *Blood*, 116(23), pp.4916-4925.
- Puvvada, S., Kendrick, S. and Rimsza, L. 2013. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. *Cancer Genetics*, 206(7-8), pp.257-265.
- Reksodiputro, A., Irawan, C., Hardjolukito, E., Suzanna, E., Rinaldi, I., Mulansari, N., et al. 2011. Non-Hodgkin's Lymphoma in Jakarta. *Indonesian Journal of Cancer*, 5(3), pp.129-133.
- Rosenwald, A., Wright, G., Chan, W., Connors, J., Campo, E., Fisher, R., et al. 2002. The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. *New England Journal of Medicine*, 346(25), pp.1937-1947.
- Said, J. (2012). Aggressive B-cell lymphomas: how many categories do we need?. *Mod Pathol*, 26, pp.S42-S56.

Sato, A., Nakamura, N., Kojima, M., Ohmachi, K., Carreras, J., Kikuti, Y., et al. 2014. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era. *Cancer Science*, 105(9), pp.1170-1175.

Soares Faccion, R., Magalhães Rezende, L., de Oliveira Romano, S., de Sá; Bigni, R., Quintella Mendes, G. and Ciuvalschi Maia, R. 2012. Centroblastic Diffuse Large B Cell Lymphoma Displays Distinct Expression Pattern and Prognostic Role of Apoptosis Resistance Related Proteins. *Cancer Investigation*, 30(5), pp.404-414.

Trajkova, S., PanovskaStavridis, I., Stojanovic, A., Petrusevska, G., Dukovski, D., Ivanovski, M., et al. 2013. Immunoblastic morphology as a possible prognostic indicator for the outcome of the patients with diffuse large B cell lymphoma in era of the rituximab based treatment: single centre experience. *Int J Res Med Sci*, 1(2), p.1.

Zinzani, P. 2014. A treatment for activated B-cell-like DLBCL?. *The Lancet Oncology*, 15(9), pp.916-917.

Zinzani, P., Broccoli, A., Stefoni, V., Musuraca, G., Abruzzese, E., De Renzo, A., et al. 2010. Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. *Cancer*, 116(24), pp.5667-5675.